Stock IMMX IMMIX BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
2.36 USD -3.67% Intraday chart for Immix Biopharma, Inc. +19.19% -65.90%
Jul. 01 HC Wainwright Initiates Immix Biopharma at Buy With $7 Price Target MT
May. 10 Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Initiates Immix Biopharma at Buy With $7 Price Target
MT
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
GL
Immix Biopharma Announces Positive NXC-201 Relapsed, Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
AQ
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
AQ
Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation
CI
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Certain Warrants of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.
CI
Certain Options of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.
CI
Certain Common Stock of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.
CI
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment
MT
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
GL
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year
MT
Immix Biopharma on Track to Dose NXC-201 Patients in United States
GL
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States
CI
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy
AQ
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
AQ
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
GL
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
AQ
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMX Stock
  4. News Immix Biopharma, Inc.